T-Cypher Bio

T-Cypher Bio is a biotechnology startup founded in 2021 and headquartered in the United Kingdom. The company's mission, encapsulated in the slogan "Unlocking an expansive target space to build a pipeline of novel, TCR-based therapeutics," reflects its core focus on generating novel TCR-based therapeutics with the potential to transform the treatment of immune-mediated disease.

By leveraging proprietary platforms, T-Cypher Bio conducts high throughput, high-resolution profiling of the immune synapse, enabling a comprehensive mapping of the intracellular target space and T cell specificity. These platforms not only facilitate the development of highly innovative drugs but also enable the generation of immune system data sets of unprecedented scale, supporting cutting-edge computational modeling of T cell repertoires that stands to revolutionize T cell immunology.

The company's approach to building its oncology pipeline involves the validation of novel, shared, tumor-specific targets and the identification of panels of rare functionally-defined T cell clones. These unique TCRs form the foundation of T-Cypher Bio's broad pipeline of lifesaving therapeutics for underserved solid tumor patients.

In December 2020, the company successfully secured a Seed Round investment of T investment from Oxford Science Enterprises, signaling early confidence in T-Cypher Bio's innovative approach and significant potential for impact within the biotechnology landscape.